Literature DB >> 24903389

Use of renin-angiotensin system blockade in patients with renal artery stenosis.

Jordana B Cohen1, Raymond R Townsend2.   

Abstract

Entities:  

Keywords:  ACE inhibitors; BP; angiotensin; renal artery stenosis; renin angiotensin system

Mesh：

Substances：

Year:  2014        PMID： 24903389      PMCID： PMC4078950          DOI： 10.2215/CJN.04240414

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  45 in total

1.  Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty.

Authors:  U Blum; B Krumme; P Flügel; A Gabelmann; T Lehnert; C Buitrago-Tellez; P Schollmeyer; M Langer
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

2.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

3.  Prediction of results of surgery for renal and renovascular hypertension.

Authors:  L I Juncos; C G Strong; J C Hunt
Journal:  Arch Intern Med       Date:  1974-10

4.  Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension.

Authors:  J J Curtis; R G Luke; J D Whelchel; A G Diethelm; P Jones; H P Dustan
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

5.  Use of renin-angiotensin inhibitors in people with renal artery stenosis.

Authors:  Kaleigh L Evans; Katherine R Tuttle; David A Folt; Taylor Dawson; Steven T Haller; Pamela S Brewster; Wencan He; Kenneth Jamerson; Lance D Dworkin; Donald E Cutlip; Timothy P Murphy; Ralph B D'Agostino; William Henrich; Christopher J Cooper
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 8.237

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.

Authors:  Hans Lithell; Lennart Hansson; Ingmar Skoog; Dag Elmfeldt; Albert Hofman; Bertil Olofsson; Peter Trenkwalder; Alberto Zanchetti
Journal:  J Hypertens       Date:  2003-05       Impact factor: 4.844

8.  Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection.

Authors:  Susan C Fagan; Anna Kozak; William D Hill; David M Pollock; Lin Xu; Maribeth H Johnson; Adviye Ergul; David C Hess
Journal:  J Hypertens       Date:  2006-03       Impact factor: 4.844

9.  Telmisartan to prevent recurrent stroke and cardiovascular events.

Authors:  Salim Yusuf; Hans-Christoph Diener; Ralph L Sacco; Daniel Cotton; Stephanie Ounpuu; William A Lawton; Yuko Palesch; Reneé H Martin; Gregory W Albers; Philip Bath; Natan Bornstein; Bernard P L Chan; Sien-Tsong Chen; Luis Cunha; Björn Dahlöf; Jacques De Keyser; Geoffrey A Donnan; Conrado Estol; Philip Gorelick; Vivian Gu; Karin Hermansson; Lutz Hilbrich; Markku Kaste; Chuanzhen Lu; Thomas Machnig; Prem Pais; Robin Roberts; Veronika Skvortsova; Philip Teal; Danilo Toni; Cam VanderMaelen; Thor Voigt; Michael Weber; Byung-Woo Yoon
Journal:  N Engl J Med       Date:  2008-08-27       Impact factor: 91.245

10.  Stent placement in patients with atherosclerotic renal artery stenosis and impaired renal function: a randomized trial.

Authors:  Liesbeth Bax; Arend-Jan J Woittiez; Hans J Kouwenberg; Willem P T M Mali; Erik Buskens; Frederik J A Beek; Branko Braam; Frans T M Huysmans; Leo J Schultze Kool; Matthieu J C M Rutten; Cornelius J Doorenbos; Johannes C N M Aarts; Ton J Rabelink; Pierre-François Plouin; Alain Raynaud; Gert A van Montfrans; Jim A Reekers; Anton H van den Meiracker; Peter M T Pattynama; Peter J G van de Ven; Dammis Vroegindeweij; Abraham A Kroon; Michiel W de Haan; Cornelis T Postma; Jaap J Beutler
Journal:  Ann Intern Med       Date:  2009-05-04       Impact factor: 25.391
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.